Biotech

ProMIS Neurosciences announced it will present preclinical data for its lead product candidate, PMN310.

ProMIS Neurosciences (TSX:PMN) announced it will present preclinical data for its lead product candidate, PMN310, at the Alzheimer’s Association International Conference (AAIC) in London in July.
As quoted in the press release:

Johanne Kaplan, Ph.D., ProMIS Chief Development Officer, will present the data and chair the associated session, entitled Preclinical: Basic Therapeutics – Targeting Amyloid or Tau.
The presentation by Kaplan (et al.), entitled Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310:  Precision drug design for Alzheimer’s disease describes the use of ProMIS’ proprietary discovery engine for the identification and generation of monoclonal antibodies against specific targets on toxic forms of amyloid beta (Ab), a recognized root cause of Alzheimer’s.
Commenting on the presentation, Dr. Kaplan stated, “Antibody PMN310 was selected as our lead product for development on the basis of its ability to selectively target and neutralize toxic Ab oligomers with no significant off-target binding to Ab monomers or fibrils. These characteristics distinguish PMN310 from other Ab antibodies currently undergoing clinical trials, and are designed to achieve optimal efficacy and safety.”

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×